Based on the survival data, we could conclude that concomitant loss of p53 and Palb2, Brca1 or Brca2 tumor-suppressor functions cooperate to dramatically augment tumorigenic potential of oncogenic mutations, such as KrasG12D. The gene discussed is PALB2; the disease is neoplasm.